Life Science Intelligence

Under the direction of CEO Leo Smit and COO Sanna Severins, Hy2CareⓇ is redefining cartilage repair through a hydrogel implant that enables natural repair of damaged cartilage — without the cost, complexity, or compromise of existing solutions. Co-founded by Dr. Sanne Both, whose personal battle with failed cartilage surgeries shaped the mission of the company, Hy2Care’s work is rooted in experience and empathy. “Sanne had three cartilage repair surgeries before she turned 24, all of which ultimately failed,” said Smit. “Her experience — and her decision to devote her PhD to solving this problem — is the reason Hy2Care exists.” The company’s lead product, CartReviveⓇ, is a hydrogel implant designed to rebuild true cartilage, not just scar tissue. As Smit put it: “We don’t offer a refinement of current options — we make a return to biology. This is a repair that lasts and is affordable.” Origin Story Hy2Care was founded in 2014 by Dr. Sanne Both and Prof. Marcel Karperien at the Univers...

Join moderator David Hochman (Orchestra BioMed, Inc.) and speaker Chris Eso (Medtronic) as they discuss groundbreaking innovations and strategic partnerships reshaping cardiac pacing, device-based hypertension therapies, and risk-reward sharing models in medtech. If you want to watch this video visit here:  https://www.lifesciencemarketresearch.com/videos/signature-series-unlocking-the-potential-of-device-based-hypertension-therapies-lsi-usa-25  

Lisa Earnhardt’s keynote at LSI USA ’25 offered a compelling look at what it takes to lead in today’s medtech landscape. Drawing from her experience scaling startups, taking companies public, and overseeing Abbott’s global medical device business, Lisa shared insights on building transformative technologies and navigating the challenges of growth, innovation, and leadership. If you want to watch this video visit here:  https://www.lifesciencemarketresearch.com/videos/keynote-with-lisa-earnhardt-executive-vice-president-group-president-medical-devices-at-abbott  

The idea for NICE Surgical was born in the operating room. Dr. Eric Haas, Chief of Colon & Rectal Surgery at Houston Methodist, had pioneered a revolutionary approach called the NICE procedure, combining Natural Orifice Specimen Extraction (NOSE) with Intracorporeal Anastomosis (ICA). The technique minimized trauma, improved outcomes, and eliminated the need for large abdominal incisions. To read more about visit here:  https://www.slideserve.com/George125/the-memo-nice-surgical-solutions-shifting-the-paradigm-in-colorectal-surgery  

After years of investing in and advising surgical innovation from the vantage point of Intuitive Ventures, Oliver Keown is stepping into the founder’s chair — with a bold new vision for the future of outpatient surgery. “At Intuitive, I had the privilege of sitting atop a giant, seeing where surgery was headed,” Keown said. “But I also saw the system’s fragmentation — and a gap no one else was addressing.” His answer is Oath Surgical, a company emerging from stealth this past week. Oath isn’t launching with a single device or platform. Instead, it’s building an entirely new surgical system — one that fuses AI, infrastructure, and incentives to power the next generation of outpatient care. Origin Story Keown’s career spans medicine, venture capital, and surgical innovation. As a trained physician and former leader of Intuitive Ventures, he’s spent the last decade evaluating the future of medtech from every angle. “I realized I had a unique opportunity — and responsibility — to act,” he ...

April was another impressive month of funding for the LSI Alumni, raising over $508 million in new capital across 20 new deals. Our monthly Alumni Funding Update features transactions made by these medical device startups and their investors, as well as links to our proprietary media and coverage of the companies themselves. Companies featured in the April 2025 update include: AMT Medical Raised $25M in Series B funding to advance the ELANAⓇ Heart Bypass System, a minimally invasive, sutureless alternative to traditional open-heart coronary artery bypass surgery. The system is designed to reduce complications, support robotic integration, and lower procedure costs by more than 50% through a standardized beating-heart technique that avoids sternotomy and bypass machines. Annaida Technologies Completed an oversubscribed Pre-Series A round to further develop its micro-magnetic resonance spectroscopy (micro-MRS) platform for non-invasive embryo assessment. Annaida Technologies will leverag...

  As we venture into Q2 of 2025, the medtech industry continues to navigate challenges while remaining on a positive growth trajectory. The early earnings reports from major medtech companies provide valuable insights into how the sector is performing and where it is heading. Despite the pressures of ongoing macroeconomic uncertainty, the first quarter of 2025 shows a sector that’s resilient, with many companies reporting strong growth across their key divisions. For more information visit here:  https://www.slideshare.net/slideshow/medtech-in-2025-key-insights-from-q1-earnings/279045324

  In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $45M in new funds, receive regulatory clearance, announce product launches, and much more on the road to   LSI Asia  ’25 in Singapore (June 10–13). AliveCor Launched the KardiaMobile® 6L Max, an AI-powered personal ECG system with the widest range of arrhythmia detection available over the counter. The company also introduced KardiaAlert, a new feature for KardiaCare subscribers that monitors ECG changes over time and alerts patients to potential risks, empowering earlier interventions and more informed care conversations. Avvio Medical Treated the first patients in its clinical trial of the Enhanced Lithotripsy System (ELS), a minimally invasive kidney stone therapy designed for outpatient settings. With IDE approval from the FDA, Avvio aims to shift treatment out of the OR and into ASCs and cystoscopy suites, eliminating the need for general anesthesia,...

  In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $35M in new funding, receive FDA 510(k) clearance, expand product lines, and much more on the road to   LSI Asia  ’25 in Singapore (June 10–13). Annaida Technologies Closed an oversubscribed Pre-Series A round to advance its micro-magnetic resonance spectroscopy (micro-MRS) platform for non-invasive embryo analysis. Annaida Technologies will use the funding to accelerate product development and expand market presence in fertility and life sciences, with its Embryospin platform already adopted in top academic labs worldwide. Azalea Vision Raised €9M in the first closing of its €15M Series A to advance its intelligent ocular health platform and support a first-in-human pilot clinical trial. Azalea Vision also appointed eyecare industry leader Robert J. Dempsey as Chairman of the Board to guide strategic growth in the United States and Europe. Bimini Health ...

Launching a new medical technology is always a gamble, but according to Ilya Trakhtenberg and Stuart Jackson of  L.E.K. Consulting , a systematic, step-by-step approach to innovation can manage risk and unlock the full potential of breakthrough innovation for organizations — far surpassing industry benchmarks. Most innovations fail. And most companies struggle with innovation. Case in point: Nearly all the growth in the S&P 500 (prior to 2025 YTD) has been driven by just seven companies, the so-called “Magnificent Seven” — Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla. Between 2013 and 2019, they delivered 19% compound returns. The other 493 companies in the index delivered just 2% in that time period. And medtech is no different: the top five market cap growers accounted for 60% of all of the industry’s market cap growth from 2015 to 2024, and a full 80% of it since 2019. Studies show that of the thousands of product launches across industries each year, 70–90% f...

Under the direction of CEO Boyle Suwono, Medulla Pro is reimagining how clinicians perform some of the most common — but error-prone — procedures in medicine. From lumbar punctures to nerve blocks, the company is building intuitive, real-time ultrasound guidance systems designed to boost precision, improve outcomes, and reduce procedural complications for patients and providers alike. “We’re giving doctors clarity and confidence — even in the most challenging cases,” Boyle said. Headquartered in Singapore, Medulla Pro is preparing to launch two products: one for lumbar punctures and one for peripheral nerve blocks. With clinical trials on the horizon, the company is moving fast — and aiming to make a meaningful difference in how care is delivered across a wide range of specialties. Origin Story Medulla Pro was born out of a real-world problem. In 2018, a Singapore-based hematologist struggled to perform a lumbar puncture on a cancer patient struggling with obesity — ultimately traumati...